Tracking the Dynamic Trajectories: A Global-to-Local Pharmacovigilance Analysis of GLP-1 Receptor Agonists
Lu, S.; Ruan, X.; Wang, L.; Wang, X.; Sameer, M.; Liu, H.
Show abstract
Although GLP1/GIP receptor agonists demonstrate unprecedented weight loss efficacy, their rapid clinical adoption has revealed significant real-world tolerability challenges. To evaluate their dynamic safety profiles, we developed a macro to micro pharmacovigilance framework by combining global FAERS reports with local UT Physician EHR. Macroscopically, we distilled 17 shared adverse events across the drug class from FAERS with disproportionality analysis. Microscopically, local EHR data (289,655 longitudinal treatment sessions across 71,316 patients) revealed 51.6% of GLP1 sessions terminated within 90 days. Furthermore, temporal stratified logistic regression demonstrated that initial exposure (0 to 30 days) correlated strongly with nausea and vomiting, which attenuated in extended sessions, whereas extended exposure (>2 years) uncovered late onset risks, notably incident hepatic steatosis. Ultimately, this time aware framework reveals that GLP1 safety profiles are profoundly duration dependent, providing critical insights into both acute intolerances and long-term medication safety.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Finding Long-COVID: Temporal Topic Modeling of Electronic Health Records from the N3C and RECOVER Programs 92%
- Federated Target Trial Emulation using Distributed Observational Data for Treatment Effect Estimation 92%
- Novel clinical subphenotypes in COVID-19: derivation, validation, prediction, temporal patterns, and interaction with social determinants of health 92%
Similar papers in this journal
Similar papers in this journal
- A Framework to Quantify Disparities in Pharmacogenomic Treatment Concordance and Drug Response Outcomes 92%
- A long-acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese non-human primate model 90%
- An untargeted metabolomics analysis of exogenous chemicals in human milk and transfer to the infant 90%
Similar papers in this journal
- Machine learning guided association of adverse drug reactions with in vitro target-based pharmacology 95%
- Multi-ancestry omic Mendelian randomization revealing putative drug targets of COVID-19 severity 90%
- A systematic analysis of the contribution of genetics to multimorbidity and comparisons with primary care data 89%
Similar papers in this journal
- Zero-shot drug repurposing with geometric deep learning and clinician centered design 93%
- The adverse impact of COVID-19 pandemic on cardiovascular disease prevention and management in England, Scotland and Wales: A population-scale analysis of trends in medication data 91%
- Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.